Commodore Capital

What Commodore Capital does

Commodore Capital is a New York-based, privately held investment management firm organized as Commodore Capital LP that deploys capital into clinical-stage and pre-commercial biopharmaceutical companies, with a stated thesis that the industry is in the early stages of a major innovation cycle driven by novel therapeutic modalities such as genetic medicines and cellular therapies. The firm serves as a financial partner to biotech issuers, providing equity capital through private placements, Series B rounds, PIPEs, and underwritten public offerings, and its portfolio spans retinal disease (Ollin Biosciences' OLN324 bispecific), CNS disorders (Alto Neuroscience's ALTO-207, LB Pharmaceuticals), oncology/radiopharmaceuticals (Perspective Therapeutics), infectious disease (AN2 Therapeutics' boron chemistry), and IBD biologics (Spyre Therapeutics). The firm is staffed by a 12-person team anchored by co-founders and managing partners Michael Kramarz, MD, MBA and Egen Atkinson, MD, MBA, supported by Partners Logan Brock and Lisa Schechner, COO/GC/CCO Ameya Bapat, and CFO Anand Pandya, with most investment professionals holding MD degrees from Harvard, Penn, NYU, or MIT HST and prior experience at specialist healthcare investors (Samlyn, RTW, Longitude, F-Prime, Roivant) or top consulting firms (Bain, McKinsey, BCG).

Commodore Capital earns revenue through the standard private-fund mechanics of management fees on assets under management and performance allocations (carried interest) on fund performance, typical of a healthcare-focused hedge fund or specialist biotech co-investment partnership; specific fee schedules and AUM are not publicly disclosed. The go-to-market is relationship-driven rather than marketing-driven: deal flow is sourced through direct professional networks built from prior healthcare investing, consulting, and pharmaceutical operating roles, and the firm is repeatedly invited to co-invest alongside tier-one specialist managers such as TCGX, ARCH Venture Partners, Andreessen Horowitz, Perceptive Advisors, RA Capital, and Vivo Capital.

The firm was founded in 2019 and is headquartered at 444 Madison Avenue, 35th Floor, New York, NY 10022. As a private limited partnership, Commodore Capital discloses neither revenue, AUM, nor ownership structure in public filings; LP and ownership information are not available in the input data, and there is no parent company, subsidiary, or public ticker. The investment program currently spans both private and public biotech securities, indicating an integrated long-biased healthcare strategy rather than a purely venture-stage posture.

Name

Commodore Capital

Legal name

Commodore Capital LP

Website

https://www.commodorecapital.com/

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Commodore Capital is a New York-based, privately held investment manager (Commodore Capital LP) that deploys equity capital into clinical-stage and pre-commercial biopharmaceutical companies developing genetic medicines, cellular therapies, and other novel therapeutics, sourcing deals through specialist healthcare networks and co-investing with tier-one biotech investors.

Ownership category

akta.pro rank

Product category

Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Biopharmaceutical investments
• Healthcare investment management
• Biotech private equity
• Clinical-stage financing
• Life sciences capital

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Management: Commodore Capital generates revenue through management fees and performance allocations (carried interest) from its investment funds, typical of private investment partnerships in the healthcare/biotech sector.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Commodore Capital is a healthcare-focused investment management firm that provides equity capital to clinical-stage and pre-commercial biopharmaceutical companies developing novel therapeutics, particularly in genetic medicines and cellular therapies. The firm invests through private placements, Series rounds, and PIPEs, serving as lead or participating investor in financings for biotech companies developing novel drug candidates.

Product overview

Commodore Capital is a biopharmaceutical investment firm that invests in innovative healthcare companies. The company focuses on funding companies developing novel therapeutic modalities such as genetic medicines and cellular therapies, with the mission of bringing safe and effective new medicines to patients worldwide. As an investment firm, Commodore Capital does not offer a technology product or platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Biopharmaceutical Investment Funds
• Private Placement Financing
• Series B Equity Investment

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Longitude Capital: Biopharma- and medtech-focused growth investor where Commodore Partner Logan Brock previously worked. Directly comparable stage focus, mandate, and team pedigree in healthcare investing.
• Foresite Capital: Healthcare-focused investment firm with crossover public/private strategy. Comparable mandate of supporting innovative biopharma companies through clinical development and into commercialization.
• OrbiMed: Dedicated healthcare investment platform spanning venture, growth, credit, and public equities. Highly comparable sector focus and lifecycle-stage breadth versus Commodore's biopharma mandate.
• Perceptive Advisors: Biotech-specialist investment firm that co-invested with Commodore in Alto Neuroscience's $120M and $50M private placements. Same clinical-stage biotech focus with crossover fund structure.
• Vivo Capital: Healthcare-dedicated investment firm that co-invested with Commodore in AN2 Therapeutics' $40M private placement. Directly comparable life sciences crossover and growth strategy.
• TCGX: Healthcare-specialist crossover investor that co-led Ollin's $330M Series B with Commodore. Same biotech focus and willingness to anchor large private and PIPE financings in clinical-stage names.
• Venrock Healthcare Capital Partners: Biopharma-focused investment franchise that co-invested with Commodore in Alto Neuroscience's $120M PIPE. Highly comparable sector mandate and stage focus on clinical-stage therapeutics.
• Baker Bros. Advisors: Long-standing, science-driven biopharma-focused investment manager with deep M.D./Ph.D. bench. Closest direct peer to Commodore in mandate, team composition, and stage focus on clinical-stage genetic medicine and novel modality companies.
• ARCH Venture Partners: Premier biotech-focused VC that co-led Ollin's $330M Series B alongside Commodore. Same frontier-science thesis (genetic medicines, cellular therapies) and similar early-to-mid-stage biopharma focus.
• RA Capital Management: Healthcare-specialist crossover and public/private investor that co-invested with Commodore in Ollin's $330M Series B. Same thesis-driven biotech focus, similar crossover structure, and comparable team pedigree.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments59 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Commodore Capital